Wednesday, December 16, 2009
Improving Outcomes in Hematologic Malignancies: Update from the ASH
51st Annual Meeting and Exposition
Statement of Need
Despite recent gains made in the management of hematologic malignancies, the treatment of these diseases remains a challenge for many healthcare professionals and patients. Formulating which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise, and available health-system resources. While difficult, these decisions require knowledge of current clinical and experimental data in order for the appropriate integration of novel therapeutic agents and strategies into clinical practice. As recently the development of novel treatment approaches have reached the clinic and have increased therapeutic options available for patients with hematologic malignancies, the future of clinical medicine within hematologic malignancies will undoubtedly come to rely more on novel agents and combinations. This educational program will provide clinicians the tools necessary to interpret clinical trial data regarding these agents, including novel combinations, and their potential place in therapy. In addition, this innovative education activity will provide the practicing hematologist/oncologist and healthcare professionals caring for patients with hematologic malignancies with the most up-to-date clinical, experimental, and safety information on the emerging hematology treatment approaches.
Target Audience
The target audience for Improving Outcomes in Hematologic Malignancies: Update from the ASH 51st Annual Meeting and Exposition includes oncologists, hematologists, and allied oncology healthcare providers caring for patients with hematologic malignancies.
Learning Objectives
Upon completion of this educational activity, participants should be better able to:
- Recognize biologic pathways of significance in hematologic malignancy pathogenesis and resistance and their implications on treatment selection and response
- Review the implications of karyotype on treatment selection and response
- Describe the potential role of novel treatment approaches in the management of hematologic malignancies
- Compare treatment options available for the treatment of patients with hematologic malignancies with respect to efficacy and toxicity parameters
|
Accreditation Information
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
|
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Educational Concepts Group, LLC designates this
continuing education activity for 1.0 contact hour
(0.10 CEU) (UAN 199-000-09-081-H01-P).
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the evaluation. For ACPE credit, participants must complete a post-test for all categories.
CME/CE CREDIT
Physicians and pharmacists who complete the evaluation may view and print their credit letter or statement of credit via the ECG website, www.educationalconcepts.net.
Click here to access archive
|
